Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T63068
(Former ID: TTDS00336)
|
|||||
| Target Name |
Serum albumin (ALB)
|
|||||
| Synonyms |
Serum albumin
|
|||||
| Gene Name |
ALB
|
|||||
| Target Type |
Successful target
|
[1] | ||||
| Disease | [+] 9 Target-related Diseases | + | ||||
| 1 | Aneurysm/dissection [ICD-11: BD50] | |||||
| 2 | Bowel habit change [ICD-11: ME05] | |||||
| 3 | Cholelithiasis [ICD-11: DC11] | |||||
| 4 | Inborn energy metabolism error [ICD-11: 5C53] | |||||
| 5 | Irritable bowel syndrome [ICD-11: DD91] | |||||
| 6 | Preprocedural examination [ICD-11: QA0B] | |||||
| 7 | Rheumatoid arthritis [ICD-11: FA20] | |||||
| 8 | Schizophrenia [ICD-11: 6A20] | |||||
| 9 | Unspecific body region injury [ICD-11: ND56] | |||||
| Function |
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Click to Show/Hide
|
|||||
| UniProt ID | ||||||
| Sequence |
MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPF
EDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEP ERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLF FAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAV ARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLK ECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYAR RHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFE QLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVV LNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTL SEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLV AASQAALGL Click to Show/Hide
|
|||||
| 3D Structure | Click to Show 3D Structure of This Target | PDB | ||||
| ADReCS ID | BADD_A00127 ; BADD_A02053 ; BADD_A02603 | |||||
| HIT2.0 ID | T18YXD | |||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Approved Drug(s) | [+] 9 Approved Drugs | + | ||||
| 1 | Albumin Human | Drug Info | Approved | Hypoalbuminemia | [2] | |
| 2 | Bismuth | Drug Info | Approved | Diarrhea | [3] | |
| 3 | EVANS BLUE | Drug Info | Approved | Abdominal aortic aneurysm | [4] | |
| 4 | Gadobenate Dimeglumine | Drug Info | Approved | Schizophrenia | [2], [5], [6] | |
| 5 | Gadofosveset | Drug Info | Approved | Imaging | [7] | |
| 6 | Iodipamide | Drug Info | Approved | Gallbladder disease | [2], [8], [9] | |
| 7 | Oxyphenbutazone | Drug Info | Approved | Arthritis | [2] | |
| 8 | Sodium lauryl sulfate | Drug Info | Approved | Constipation | [10] | |
| 9 | SPI-1005 | Drug Info | Approved | Reperfusion injury | [11] | |
| Clinical Trial Drug(s) | [+] 3 Clinical Trial Drugs | + | ||||
| 1 | Activated recombinant FVII-albumin fusion protein | Drug Info | Phase 2/3 | Hemophilia | [12] | |
| 2 | Vobarilizumab | Drug Info | Phase 2 | Rheumatoid arthritis | [13] | |
| 3 | RU-101 | Drug Info | Phase 1/2 | Xerophthalmia | [14] | |
| Mode of Action | [+] 3 Modes of Action | + | ||||
| Modulator | [+] 6 Modulator drugs | + | ||||
| 1 | Albumin Human | Drug Info | [15] | |||
| 2 | EVANS BLUE | Drug Info | [4] | |||
| 3 | Gadofosveset | Drug Info | [7] | |||
| 4 | Oxyphenbutazone | Drug Info | [18] | |||
| 5 | Activated recombinant FVII-albumin fusion protein | Drug Info | [21] | |||
| 6 | RU-101 | Drug Info | [23] | |||
| Binder | [+] 5 Binder drugs | + | ||||
| 1 | Bismuth | Drug Info | [16] | |||
| 2 | Gadobenate Dimeglumine | Drug Info | [1] | |||
| 3 | Iodipamide | Drug Info | [17] | |||
| 4 | Sodium lauryl sulfate | Drug Info | [19] | |||
| 5 | SPI-1005 | Drug Info | [20] | |||
| Inhibitor | [+] 1 Inhibitor drugs | + | ||||
| 1 | Vobarilizumab | Drug Info | [22] | |||
| Chemical Structure based Activity Landscape of Target | Top |
|---|---|
| Drug Property Profile of Target | Top | |
|---|---|---|
| (1) Molecular Weight (mw) based Drug Clustering | (2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering | |
|
|
||
| (3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering | (4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering | |
|
|
||
| (5) Rotatable Bond Count (rotbonds) based Drug Clustering | (6) Topological Polar Surface Area (polararea) based Drug Clustering | |
|
|
||
| "RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five | ||
| Co-Targets | Top | |||||
|---|---|---|---|---|---|---|
| Co-Targets | ||||||
| Target Poor or Non Binders | Top | |||||
|---|---|---|---|---|---|---|
| Target Poor or Non Binders | ||||||
| Target Regulators | Top | |||||
|---|---|---|---|---|---|---|
| Target-regulating microRNAs | ||||||
| Target Profiles in Patients | Top | |||||
|---|---|---|---|---|---|---|
| Target Expression Profile (TEP) | ||||||
| Target Affiliated Biological Pathways | Top | |||||
|---|---|---|---|---|---|---|
| PID Pathway | [+] 1 PID Pathways | + | ||||
| 1 | FOXA2 and FOXA3 transcription factor networks | |||||
| Reactome | [+] 4 Reactome Pathways | + | ||||
| 1 | Platelet degranulation | |||||
| 2 | Recycling of bile acids and salts | |||||
| 3 | HDL-mediated lipid transport | |||||
| 4 | Scavenging of heme from plasma | |||||
| WikiPathways | [+] 8 WikiPathways | + | ||||
| 1 | Human Complement System | |||||
| 2 | Binding and Uptake of Ligands by Scavenger Receptors | |||||
| 3 | Lipid digestion, mobilization, and transport | |||||
| 4 | Transport of vitamins, nucleosides, and related molecules | |||||
| 5 | Bile acid and bile salt metabolism | |||||
| 6 | Folate Metabolism | |||||
| 7 | Vitamin B12 Metabolism | |||||
| 8 | Selenium Micronutrient Network | |||||
| Target-Related Models and Studies | Top | |||||
|---|---|---|---|---|---|---|
| Target Validation | ||||||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Protocol design for high relaxivity contrast agents in MR imaging of the CNS. Eur Radiol. 2006 Nov;16 Suppl 7:M3-7. | |||||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||||
| REF 3 | The effect of histamine H2-receptor blockade on bismuth absorption from three ulcer-healing compounds. Gastroenterology. 1991 Oct;101(4):889-94. | |||||
| REF 4 | The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. | |||||
| REF 5 | 2004 approvals: the demise of the blockbuster. Nat Rev Drug Discov. 2005 Feb;4(2):93-4. | |||||
| REF 6 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 021357. | |||||
| REF 7 | 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. | |||||
| REF 8 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7400). | |||||
| REF 9 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 009321. | |||||
| REF 10 | Drug information of Sodium lauryl sulfate, 2008. eduDrugs. | |||||
| REF 11 | Advances in ischemic stroke treatment: neuroprotective and combination therapies. Expert Opin Emerg Drugs. 2007 Mar;12(1):97-112. | |||||
| REF 12 | ClinicalTrials.gov (NCT02484638) Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors. | |||||
| REF 13 | ClinicalTrials.gov (NCT02518620) An Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of ALX-0061 in Subjects With Rheumatoid Arthritis. U.S. National Institutes of Health. | |||||
| REF 14 | ClinicalTrials.gov (NCT01843894) A Phase 1/2, RU-101 Ophthalmic Solution in Patients With Severe Dry Eye. U.S. National Institutes of Health. | |||||
| REF 15 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||||
| REF 16 | Competitive binding of bismuth to transferrin and albumin in aqueous solution and in blood plasma. J Biol Chem. 2001 Mar 23;276(12):8829-35. | |||||
| REF 17 | Determining binding sites of drugs on human serum albumin using FIA-QCM. Biosens Bioelectron. 2008 Sep 15;24(1):48-54. | |||||
| REF 18 | Effect of albumin conformation on binding of phenylbutazone and oxyphenbutazone to human serum albumin. J Pharm Sci. 1982 Feb;71(2):241-4. | |||||
| REF 19 | Some properties of the interaction between 2,2'-diselenadibenzoic acid and serum albumins. J Pharm Biomed Anal. 2005 Sep 1;39(1-2):263-7. | |||||
| REF 20 | Transport of ebselen in plasma and its transfer to binding sites in the hepatocyte. Biochem Pharmacol. 1994 Sep 15;48(6):1137-44. | |||||
| REF 21 | ClinicalTrials.gov (NCT01542619) A Safety and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor VIIa With Albumin (rVIIa-FP) in Healthy Male Volunteers. U.S. National Institutes of Health. | |||||
| REF 22 | Clinical pipeline report, company report or official report of Ablynx. | |||||
| REF 23 | Albumin as a tear supplement in the treatment of severe dry eye. Br J Ophthalmol. 2003 October; 87(10): 1279-1283. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.